Step 1 topics → Immunology → T Cell Activation and Costimulation

T Cell Activation and Costimulation

USMLE Step 1 trap: Confuses T cell anergy (functional unresponsiveness) with apoptosis when costimulation is absent. A T cell receiving signal 1 without signal 2 becomes anergic — functionally unresponsive — rather than undergoing apoptosis.

T cell activation requires two distinct signals delivered simultaneously — this is one of the most tested immunology concepts on USMLE Step 1. Signal 1 is antigen-specific: the TCR recognizes peptide presented on MHC. Signal 2 is costimulatory: CD28 on the T cell binds B7 (CD80/CD86) on the APC. Without both signals firing together, the T cell doesn't just fail to activate — it enters a specific state called anergy. The exam loves this distinction.

Step 1 tests this concept from several angles. Mechanistic questions ask what happens when signal 2 is absent. Pharmacology questions tie in checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) and require you to know which molecular brake each one releases. Passage-based questions may describe a tumor microenvironment scenario and ask why T cells are functionally suppressed despite being present. The CTL killing mechanism is also tested — expect to trace the path from CTL activation to target cell apoptosis.

The three classic traps here: thinking anergy means apoptosis (it doesn't — the cell survives but is unresponsive), thinking CTLA-4 and PD-1 are interchangeable (they operate in completely different compartments at different stages), and thinking CTLs kill via antibodies or complement (they don't — that's B cell territory). Nail these distinctions and you'll handle any T cell activation question USMLE Step 1 throws at you.

From real student decks
81%have cards covering this topic
68%have mature cards

Common misconceptions

Common mistake
Wrong: A T cell receiving only signal 1 (TCR–MHC) without signal 2 (CD28–B7) will undergo apoptosis.
Right: A T cell receiving signal 1 without signal 2 becomes anergic — functionally unresponsive — rather than undergoing apoptosis.
Anergy and apoptosis are not the same outcome. When a T cell gets Signal 1 (TCR–MHC engagement) without Signal 2 (CD28–B7 costimulation), the cell survives but becomes functionally frozen — it can't proliferate or produce IL-2, even if it encounters the same antigen again with full costimulation later. This is the body's mechanism for tolerating self-antigens presented by non-professional APCs that lack B7. Think of anergy as a permanent 'off switch,' not cell death.
Common mistake
Wrong: CTLA-4 and PD-1 both function at the same stage of T cell activation and in the same tissue compartment.
Right: CTLA-4 competes with CD28 for B7 on APCs in lymph nodes to dampen early T cell priming, while PD-1 binds PD-L1/L2 in peripheral tissues to suppress effector T cell activity at the tumor or infection site.
CTLA-4 and PD-1 are both inhibitory receptors on T cells, but they do completely different jobs at different times and places. CTLA-4 is upregulated early during T cell priming in the lymph node — it outcompetes CD28 for B7 and slams the brakes on activation before the T cell fully commits. PD-1 comes into play later, in peripheral tissues, where it binds PD-L1 (expressed by tumors, chronically infected cells, and normal tissues) to suppress effector T cells on-site. This is why ipilimumab (anti-CTLA-4) and nivolumab/pembrolizumab (anti-PD-1) have overlapping but distinct clinical profiles and toxicities.
Common mistake
Wrong: CTLs kill target cells primarily by releasing antibodies or activating complement.
Right: CTLs kill target cells via perforin/granzyme-mediated apoptosis and Fas–FasL interaction, both converging on caspase activation; they do not use antibodies or complement.
CTLs are CD8+ T cells — they don't make antibodies and they don't activate complement. Their killing toolkit is entirely cell-contact-dependent and apoptosis-focused: perforin punches pores in the target cell membrane, granzymes enter and directly activate caspases, and Fas ligand on the CTL binds Fas on the target cell to trigger the extrinsic apoptosis pathway. Both routes converge on caspase activation and programmed cell death. Antibody-mediated and complement-mediated cytotoxicity are humoral mechanisms — a completely separate arm of immunity.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the two-signal requirement for T cell activation: Signal 1 (TCR–MHC) plus Signal 2 (CD28–B7) are both required; receiving Signal 1 alone drives the T cell into anergy — functional unresponsiveness — not apoptosis.
  2. Understand CTLA-4 vs. PD-1 as distinct checkpoints: CTLA-4 competes with CD28 for B7 on APCs in lymph nodes and dampens early priming, while PD-1 is engaged in peripheral tissues (tumor sites, infection sites) to suppress already-activated effector T cells — and know which checkpoint inhibitor drugs block each.
  3. Trace the CTL killing mechanism: Cytotoxic T lymphocytes kill target cells via perforin/granzyme-mediated apoptosis and Fas–FasL signaling, both converging on caspase activation — not through antibodies or complement.

Can you avoid these mistakes?

A self-reactive T cell in the thymus escapes deletion and enters the periphery. It encounters its self-antigen presented on MHC II by a tissue cell that lacks B7 expression. What happens to this T cell, and what is the mechanism?
A cancer patient is started on ipilimumab and develops severe colitis. What checkpoint does this drug target, where does that checkpoint normally function, and why might blocking it cause autoimmune-like side effects in the gut?
A patient with a viral infection has CD8+ T cells infiltrating the infected tissue, but viral titers remain high. Biopsy shows high PD-L1 expression on infected cells. Explain the molecular mechanism by which the virus is evading CTL killing, and name a drug class that could reverse this.
A CD8+ CTL recognizes a virally infected cell and forms an immunological synapse. Trace the sequence of events from TCR engagement to target cell death, naming at least two distinct killing mechanisms and the final common pathway they share.

Related topics

MHC Class I and II Thymus and T Cell Maturation Spleen Architecture and Function Lymph Node and MALT Architecture Innate Immune Cells Overview

See how your Anki deck covers this topic.

Upload your deck for a free audit →